Tag: biotechnology
-
Start-Up Lands $10M for Gene-Editing HIV Treatments
A new enterprise developing treatments using gene editing to eliminate HIV infections received $10 million in its seed funding round.
-
Field Tests of Genetically Modified Moths to Begin
Outdoor tests of a genetically engineered diamondback moth, a difficult agricultural pest, altered to stop reproducing and collapse the species, are about to get underway.
-
Engineered T-Cell Trials Stopped after Patient Death
The Food and Drug Administration stopped two clinical trials testing genetically engineered T-cells from the immune system to treat leukemia, after a participant in one trial died.
-
Trial Underway Testing Alzheimer’s-Schizophrenia Drug
A new clinical trial began in the U.K. in a test of an experimental drug to treat schizophrenia associated with Alzheimer’s disease.
-
Simple Cell Programming Designed for Gene Therapies
A simpler technique using nanoscale particles was shown in lab tests to deliver messenger RNA to reprogram cells for gene therapies, including changes in T-cells in the immune system now approved to treat a type of leukemia.
-
Engineered T-Cell Company Acquired for $11.9 Billion
A company developing personal cancer therapies that genetically engineer a patient’s immune system cells is being acquired in a deal valued at $11.9 billion.
-
Forensic Genomics Company Spun-Off From Illumina
A new company is being established to provide genomics analysis systems for law enforcement, spun-off from a leading maker of genomics systems.
-
Engineered Insulin-Producing Cells to Be Grown in Lab
A team from three universities is developing in the lab synthetic islet cells, the cells that produce insulin in the pancreas, for eventual transplantation in people with type 1 diabetes.
-
Vaccines in Development for Opioid Combinations
Researchers studying the immune system as a weapon against opioid addiction say they can develop vaccines that block combinations of opioids, like those sold on the street.
-
AstraZeneca, Biotech Partner on Messenger RNA Therapies
Global drug maker AstraZeneca is acquiring an option to license the rights to a technology based on genetic material transcribed from DNA, for new respiratory disease treatments.